Evidence map›Paper›PMID 30584410›Full record

ArticleJournal of medical biochemistry2018

Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes.

İbrahim Halil Demirsoy, Duygu Yolal Ertural, Şenay Balci, Ümit Çınkır, Kerem Sezer, Lülüfer Tamer, Nurcan Aras

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Observational
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. The role of microRNAs in pregnancies complicated by maternal diabetes.Clinical science (London, England : 1979) · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

İbrahim Halil DemirsoyDepartment of Medical Biology, Mersin University, Mersin, Turkey.
Duygu Yolal ErturalDepartment of Medical Biology, Mersin University, Mersin, Turkey.
Şenay BalciDepartment of Medical Biochemistry, Mersin University, Mersin, Turkey.
Ümit ÇınkırDepartment of Endocrinology and Metabolism, Mersin University, Mersin, Turkey.
Kerem SezerDepartment of Endocrinology and Metabolism, Mersin University, Mersin, Turkey.
Lülüfer TamerDepartment of Medical Biochemistry, Mersin University, Mersin, Turkey.
Nurcan ArasDepartment of Medical Biology, Mersin University, Mersin, Turkey.
Mersin Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetformin, a widely used biguanide class of anti-diabetic drug, has potential to increase insulin sensitivity and reduce blood glucose to treat type 2 diabetes (T2D). It has been reported that metformin has an activity on regulation of miRNAs by targeting several downstream genes in metabolic pathways. However, molecular mechanism underlying the process is still not fully known. In this study, it was aimed to identify differential expression profiles of plasma derived miRNAs following 3 months metformin treatment in patients with T2D.

methodsThe plasma samples of 47 patients with T2D (received no anti-diabetic treatments) and plasma samples of same 47 patients received 3 months metformin treatment was recruited to the study. Total RNAs were isolated from plasma and reverse transcribed into cDNA. Profiles of differential expressions of miRNAs in plasma were assessed by using of micro-fluidic based multiplex quantitative real time -PCR (BioMarkTM 96.96 Dynamic Array).

resultsOur results showed that expression profiles of 13 candidate miRNAs; hsa-let-7e-5p, hsa-let-7f-5p, hsa-miR- 21-5p, hsa-miR-24-3p, hsa-miR-26b-5p, hsa-miR-126-5p, hsa-miR-129-5p, hsa-miR-130b-3p, hsa-miR-146a-5p, hsamiR- 148a-3p, hsa-miR-152-3p, hsa-miR-194-5p, hsa-miR- 99a-5p were found significantly downregulated following metformin treatments in patients with T2D (p<0.05).

conclusionsIn conclusion, our finding could provide development of better and more effective miRNAs based therapeutic strategies against T2D.

Indexed as

metforminmiRNAsqRT-PCRT2D

Identifiers

PMID30584410
PMCPMC6298473
OpenAlexW2800667086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.